Fig. 5: Phage combination screening and manufacturing, and quality control of Entelli-02 phage product.
a, Host-range coverage of phage combinations (G and I) tested against 156 ECC isolates on the basis of spot assay data. b, Comparison of phage scores of combinations G and I against ECC isolates. Each dot represents a phage score (n = 67). p values were calculated using a two-tailed t-test with Welch’s correction. Dashed line (<0.28) indicates the threshold for characterizing a phage activity as productive. c, Host-range coverage (n = 156) of phage combinations (G and I), based on combined phage score and spot assay data. d, Schematic representation of the two-stage therapeutic-grade phage production protocol developed by the Monash Phage Foundry. e, Phage titre at each production stage. Each data point represents results from three biological replicates. Each boxplot color represents a specific phage shown at the top of the graph. Whiskers indicate maximum and minimum values, individual points beyond whiskers are outliers, box bounds indicate 25th and 75th percentiles, and centre line indicates the median. f, Endotoxin activity as EU per ml of pure lysate [stage 2 (iii)] and the final product [stage 2 (vi)]. g, TEM images of phage product Entelli-02 showing intact virions and no contaminants. h, Normalized relative coverage (relative abundance) of sequencing reads from Entelli-02 against each component phage and predicted prophages from the clinical ECC production strains. i, Phage titre stability of the packaged Entelli-02 product with storage at 4 °C in 1× PBS supplemented with 1 mM CaCl2 over 18 months (M). Data represent mean ± s.e.m of 2 biological replicates. Panel d created with BioRender.com.
